Cilofexor plus firocostat well tolerated by patients with fibrosis due to NASH

Cilofexor plus firsocostat for 48 weeks was safe and well tolerated in patients with fibrosis due to nonalcoholic steatohepatitis, according to research presented at The Digital International Liver Congress.“Cilofexor plus firsocostat led to a nonsignificant but higher rate of fibrosis improvement without worsening of NASH and reduced progression to cirrhosis vs. placebo,” Rohit LoombaMD, MHSc, from the division of gastroenterology at the University of California at San Diego, said during his presentation.In the ATLAS phase 2b trial, Loomba and colleagues randomly assigned 392Read More

Share on facebook
Share on twitter
Share on linkedin